Generation Bio Co. (GBIO)
NASDAQ: GBIO · Real-Time Price · USD
0.4271
+0.0065 (1.55%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Company Description
Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells.
It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise mechanism of target engagement could unlock a series of high-value historically undruggable disease-driving genes in autoimmunity.
The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017.
Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Generation Bio Co.
| Country | United States |
| Founded | 2016 |
| IPO Date | Jun 12, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 115 |
| CEO | Cameron McDonough |
Contact Details
Address: 301 Binney Street Cambridge, Massachusetts 02142 United States | |
| Phone | 617 655 7500 |
| Website | generationbio.com |
Stock Details
| Ticker Symbol | GBIO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001733294 |
| CUSIP Number | 37148K100 |
| ISIN Number | US37148K1007 |
| Employer ID | 81-4301281 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Cameron Geoffrey McDonough M.D. | President, Chief Executive Officer and Director |
| Yalonda Howze J.D. | Chief Legal Officer and Secretary |
| Dr. Mark D. Angelino Ph.D. | Co-Founder |
| Dr. Robert Kotin Ph.D. | Co-Founder |
| Kevin John Conway | Chief Financial Officer |
| Antoinette Paone M.B.A., M.S. | Chief Operating Officer |
| Jasmin Tower | Chief Human Resources Officer |
| Dr. Phillip Samayoa Ph.D. | Chief Scientific Officer |
| Caitlin Cooper M.B.A. | Senior Vice President and Head of Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2025 | ARS | Filing |
| Apr 23, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 11, 2025 | PRE 14A | Other preliminary proxy statements |
| Mar 13, 2025 | 10-K | Annual Report |
| Mar 13, 2025 | 8-K | Current Report |
| Feb 28, 2025 | 8-K | Current Report |
| Feb 12, 2025 | SCHEDULE 13G/A | Filing |
| Jan 6, 2025 | 8-K | Current Report |
| Jan 3, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |